Expertise in
13
conditions

Stephane Decramer

Toulouse, FR 
Expertise in
13
conditions
Toulouse, FR 

Overview

Stephane Decramer practices practicing medicine in Toulouse, France.

Ms. Decramer is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Posterior Urethral Valves, Bartter Syndrome, Henoch-Schonlein Purpura, Nephrocalcinosis, and Kidney Transplant.

She is actively involved in clinical research, co-authoring 98 peer reviewed articles and participating in 5 clinical trials.

Gender

Female

Locations

Toulouse, France
Other Locations
Limoges, France
Lyon, France
Paris, France
Bordeaux, 33076, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo
Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo
Enrollment Status: Completed
Publish Date: May 04, 2026
Intervention Type: Drug
Study Phase: Phase 3
A Multicentre, Randomized, Controlled Versus Placebo, Double-blinded, 4 Parallel Arms, Dose-ranging Main Study, to Evaluate the Efficacy, Safety and Tolerability and Acceptability of Repeated Doses of ADV7103, After 7 Days of Treatment, in Patients With Cystinuria, and an Efficacy and Safety Exploratory Study in the Youngest Children.
A Multicentre, Randomized, Controlled Versus Placebo, Double-blinded, 4 Parallel Arms, Dose-ranging Main Study, to Evaluate the Efficacy, Safety and Tolerability and Acceptability of Repeated Doses of ADV7103, After 7 Days of Treatment, in Patients With Cystinuria, and an Efficacy and Safety Exploratory Study in the Youngest Children.
Enrollment Status: Withdrawn
Publish Date: January 08, 2026
Intervention Type: Drug
Study Drug: ADV7103
Study Phase: Phase 2/Phase 3
Open Label, Multicentre Study, Evaluating the Safety, Tolerability, Efficacy, Compliance and Acceptability of Alkalising Treatments at Long-term in Patients With Cystinuria
Open Label, Multicentre Study, Evaluating the Safety, Tolerability, Efficacy, Compliance and Acceptability of Alkalising Treatments at Long-term in Patients With Cystinuria
Enrollment Status: Withdrawn
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drugs: ADV7103, Standard of Care
Study Phase: Phase 2/Phase 3
Study of Ovarian Function and Gynecological Profile of Patients Carrying a Pathogenic Variant of the HNF1B Gene (GYN-HNF1)
Study of Ovarian Function and Gynecological Profile of Patients Carrying a Pathogenic Variant of the HNF1B Gene (GYN-HNF1)
Enrollment Status: Completed
Publish Date: February 15, 2024
Intervention Type: Biological, Other
Study Phase: Not Applicable
An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent CKD Patients With Hyperphosphataemia
An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent CKD Patients With Hyperphosphataemia
Enrollment Status: Terminated
Publish Date: September 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

98 Total Publications

Prenatal body fluid analysis in the evaluation of CAKUT.
Prenatal body fluid analysis in the evaluation of CAKUT.
Journal: Pediatric nephrology (Berlin, Germany)
Published: March 16, 2026

Frequently Asked Questions about Stephane Decramer

Is Stephane Decramer a top-rated expert for Posterior Urethral Valves?

MediFind is an objective health platform that identifies experts based on real-world data. Stephane Decramer is classified as an Distinguished expert for Posterior Urethral Valves, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Stephane Decramer participate in research or clinical trials?

Yes. Stephane Decramer has published 98 articles and abstracts on conditions like Posterior Urethral Valves. You can view a list of Stephane Decramer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Decramer's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 41 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile